REPROCELL Corporate News (2)

New collaboration at Hartree National Centre for Digital Innovation combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in artificial intelligence and machine...

Glasgow UK - 17 August 2022: A drug being developed for the treatment of severe asthma and COPD has passed an important milestone. Scientists at REPROCELL compared the effects of the compound,...

Next month, the Safety Pharmacology Society (SPS) will be hosting its first in-person meeting since 2019. Now in its 22nd year, this dynamic forum is known for its global networking opportunities and...

Hyderabad, India - 9 August 2022: We are pleased to announce that Bioserve Biotechnologies India Pvt Ltd, a subsidiary of REPROCELL Inc, has received NABL (National Accreditation Board for Testing...

This June, REPROCELL’s experts will be busy. We will be joining with stem cell scientists at ISSCR 2022 to allow scientists an opportunity to meet in person with REPROCELL’s experts at Booth 310 and...

Yokohama Japan, 16 May 2022: We are pleased to announce that the Clinical Phase II Trial of Stemchymal, a regenerative medicine product derived from somatic stem cells, has been completed in Japan....

Glasgow UK - 25 February 2022: REPROCELL, in collaboration with researchers at IBM and the Precision Medicine Scotland Innovation Centre, have co-authored a publication aiming to improve precision...

Glasgow UK - 21 January 2022: REPROCELL has published an article highlighting the power of human biospecimens in the latest issue of European Biopharmaceutical Review (EBR). The piece, titled...

Yokohama Japan, 8 November 2021: REPROCELL has signed a new agency agreement with Ajinomoto Group for the marketing and sale of StemFit Basic03 GMP and GMP compliant recombinant human bFGF. These...

GLASGOW, October 25, 2021: Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel...

Hyderabad India – 15 September 2021: Bioserve Biotechnologies India Pvt. Ltd. (a 100% owned subsidiary of REPROCELL Inc) will sponsor a webinar series hosted by the Society of Fetal Medicine in...

Yokohama Japan, 02 September 2021: REPROCELL have signed a Strategic Collaboration Agreement with TEXCELL JAPAN, a TEXCELL Group Company, for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The...

Yokohama Japan, 18 August 2021: REPROCELL have signed a Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group...

Glasgow, UK: REPROCELL employees, Zara Puckrin and Graeme Macluskie, have published a headline article in the latest issue of European Biopharmaceutical Review (EBR). The piece, titled "Human Fresh...

Maryland, USA: REPROCELL has opened a new Seed iPSC Manufacture Suite (SiMS) in response to increasing demand for iPSC-derived Master Cell Banks (MCBs). At this new US facility, REPROCELL will...

Yokohama, Japan: We are pleased to announce that REPROCELL will launch a new testing service of identification for Covid-19 variants, including the Indian (Delta), UK, South African, and Brazilian...

We are pleased to announce that administrations of Stemchymal, a regenerative medicine product derived from somatic stem cells, have been completed to all enrolled patients in phase II clinical trial...

Rotterdam, the Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to...

REPROCELL USA and REPROCELL Europe will be attending all 5 days of the Biotechgate Digital Partnering 2021 Event, 3-7 May 2021. Partnering scheduling is now open, and registration is free. Have a...

Hyderabad India – 19 April 2021: Bioserve Biotechnologies India Pvt Ltd, a 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of clinical oncology diagnostic service in India....